Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms of Novel HIV Therapy PRO 140
Both intravenous and subcutaneous forms of PRO 140 showed potent and prolonged activity and were generally well tolerated
29-Oct-2008 -
Progenics Pharmaceuticals, Inc. announced positive interim results from two separate phase 2 clinical trials of PRO 140 for the treatment of HIV infection. Both intravenous and subcutaneous forms of PRO 140, a viral-entry inhibitor, exhibited potent and prolonged activity as measured by ...
chemotherapy
clinical trials
infectious diseases
+6